Lisata Therapeutics
LSTA
28 hedge funds and large institutions have $4.25M invested in Lisata Therapeutics in 2018 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 5 closing their positions.
1,450% more call options, than puts
Call options by funds: $31K | Put options by funds: $2K
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
13% more capital invested
Capital invested by funds: $3.77M → $4.25M (+$480K)
0.06% less ownership
Funds ownership: 0.52% → 0.46% (-0.06%)
10% less funds holding
Funds holding: 31 → 28 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$233K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$92.3K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$44.3K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$40.9K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$31.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$118K |
| 2 |
JP Morgan Chase
New York
|
-$110K |
| 3 |
STA
Summit Trail Advisors
New York
|
-$73K |
| 4 |
Millennium Management
New York
|
-$62K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$50.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RE
26
RBC Europe
London,
United Kingdom
| $65 | – | – | – |
|
|
27
JP Morgan Chase
New York
| – | -$110K | -1,251 | Closed |
|
|
STA
28
Summit Trail Advisors
New York
| – | -$73K | -1,182 | Closed |
|
|
29
Millennium Management
New York
| – | -$62K | -708 | Closed |
|
LSTA Hedge Fund Activity: Q2 2018 in Review
28 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q2 2018, worth a combined $4.25M — up 13% from $3.77M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of LSTA and 2 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 9 added.
The largest buyer was Renaissance Technologies, adding an estimated $233K. The largest seller was Macquarie Group, cutting an estimated $118K.
- 28 institutional investors held Lisata Therapeutics (LSTA) as of Q2 2018, down from 31 in Q1 2018.
- Funds reported $4.25M of Lisata Therapeutics stock for Q2 2018, up 13% quarter-over-quarter.
- 2 funds opened new Lisata Therapeutics positions in Q2 2018 and 5 closed out, a net change of -3 holders.
- The largest Lisata Therapeutics buyer in Q2 2018 was Renaissance Technologies, an estimated $233K added.
- The largest Lisata Therapeutics seller in Q2 2018 was Macquarie Group, an estimated $118K sold.
Based on aggregated 13F filings for Q2 2018.